- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
History of Medical Cannabis in Washington
In 1998, Washington voters approved state Initiative Measure No. 692, allowing a qualifying patient or designated provider to have a 60-day supply of medical cannabis, later defined as 24 ounces and 15 plants. Under the measure qualifying patients and caregivers within those limits are protected from arrest and prosecution, and a patient who exceeds those limits is entitled to a medical defense of medical necessity. Designated providers must be 18 years of age or older.
Legal retail access for patients at dispensaries was not permitted under Washington law until voters approved I-502 authorizing an adult-use commercial cannabis program in 2012. However Washington did allow patients participating in cooperatives to grow cannabis, and these provisions of the state's medical cannabis laws remain in place today. Acknowledging the lack of insurance options available to subsidize the costs of medical cannabis, the state shields cannabis patients from state and local taxes applied to legal cannabis at retail establishments.
In 2017, Washington passed SB 5131, which provided a slight improvement to Washington's medical access market. The bill allows qualifying medical card holders in the state database to purchase immature plants, clones, and seeds directly from licensed cultivators authorized by the state to conduct these activities. SB 5131 also implemented a few technical changes, including provisions related to consulting agreements, advertising restrictions, research, and qualifications for organic cannabis.
In 2018, regulators released new packaging and labeling requirements, as well as the state's first research license. In 2019, the state temporarily suspended the requirement that cannabis products be tested for heavy metal because there were no labs certified to do so. A lack of laboratory testing creates an enormous safety problem for patients. While there was only a temporary period where heavy metal testing was suspended, any time where legal products are untested and made available to patients is too long.